Literature DB >> 29267408

Standard or networked meta-analyses in assessing the best option for neo-adjuvant therapy in resectable oesophageal cancer: chemotherapy or chemo-radiotherapy?

Ewen A Griffiths1, Sandro Pasquali2, Ravinder S Vohra3.   

Abstract

Entities:  

Year:  2017        PMID： 29267408      PMCID： PMC5723905          DOI： 10.21037/jtd.2017.09.120

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

Review 1.  What is the best neoadjuvant regimen prior to oesophagectomy: chemotherapy or chemoradiotherapy?

Authors:  Emma Hamilton; Ravinder S Vohra; Ewen A Griffiths
Journal:  Int J Surg       Date:  2013-12-19       Impact factor: 6.071

Review 2.  Demystifying trial networks and network meta-analysis.

Authors:  Edward J Mills; Kristian Thorlund; John P A Ioannidis
Journal:  BMJ       Date:  2013-05-14

3.  Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study.

Authors:  F Favi; E Bollschweiler; F Berlth; P Plum; D A Hescheler; H Alakus; R Semrau; E Celik; S P Mönig; U Drebber; A H Hölscher
Journal:  Eur J Surg Oncol       Date:  2017-06-16       Impact factor: 4.424

4.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Authors:  Marc Ychou; Valérie Boige; Jean-Pierre Pignon; Thierry Conroy; Olivier Bouché; Gilles Lebreton; Muriel Ducourtieux; Laurent Bedenne; Jean-Michel Fabre; Bernard Saint-Aubert; Jean Genève; Philippe Lasser; Philippe Rougier
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

5.  Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study).

Authors:  Kenichi Nakamura; Ken Kato; Hiroyasu Igaki; Yoshinori Ito; Junki Mizusawa; Nobutoshi Ando; Harushi Udagawa; Yasuhiro Tsubosa; Hiroyuki Daiko; Shuichi Hironaka; Haruhiko Fukuda; Yuko Kitagawa
Journal:  Jpn J Clin Oncol       Date:  2013-04-26       Impact factor: 3.019

6.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Authors:  Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski
Journal:  Lancet Oncol       Date:  2011-06-16       Impact factor: 41.316

Review 7.  Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis.

Authors:  Sandro Pasquali; Guang Yim; Ravinder S Vohra; Simone Mocellin; Donald Nyanhongo; Paul Marriott; Ju Ian Geh; Ewen A Griffiths
Journal:  Ann Surg       Date:  2017-03       Impact factor: 12.969

8.  A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.

Authors:  F Klevebro; G Alexandersson von Döbeln; N Wang; G Johnsen; A-B Jacobsen; S Friesland; I Hatlevoll; N I Glenjen; P Lind; J A Tsai; L Lundell; M Nilsson
Journal:  Ann Oncol       Date:  2016-01-17       Impact factor: 32.976

9.  ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).

Authors:  Jens Hoeppner; Florian Lordick; Thomas Brunner; Torben Glatz; Peter Bronsert; Nadine Röthling; Claudia Schmoor; Dietmar Lorenz; Christian Ell; Ulrich T Hopt; J Rüdiger Siewert
Journal:  BMC Cancer       Date:  2016-07-19       Impact factor: 4.430

10.  ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS).

Authors:  J V Reynolds; S R Preston; B O'Neill; L Baeksgaard; S M Griffin; C Mariette; S Cuffe; M Cunningham; T Crosby; I Parker; K Hofland; G Hanna; L B Svendsen; C L Donohoe; C Muldoon; D O'Toole; C Johnson; N Ravi; G Jones; A K Corkhill; M Illsley; J Mellor; K Lee; M Dib; V Marchesin; M Cunnane; K Scott; P Lawner; S Warren; S O'Reilly; G O'Dowd; G Leonard; B Hennessy; R Mc Dermott
Journal:  BMC Cancer       Date:  2017-06-03       Impact factor: 4.430
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.